Brief: Effector Therapeutics Enters Into Investment Agreement With Lincoln Park Capital For Up To $50 Mln
Jan 24 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS INC - ENTERS INTO INVESTMENT
AGREEMENT
WITH LINCOLN PARK CAPITAL FOR UP TO $50 MILLION
* EFFECTOR THERAPEUTICS-SEES EXISTING CASH RESOURCES TO
ALLOW READ
OUT INITIAL RESPONSE, TOPLINE RESULTS FROM ZOTATIFIN PHASE 2A
DOSE-EXPANSION COHORTS
* EFFECTOR THERAPEUTICS - EXPECTS EXISTING CASH RESOURCES
WILL
ALLOW READ OUT OF TOPLINE DATA FROM BOTH ACTIVE COHORTS IN
PHASE 2B KICKSTART TRIAL
Source text for Eikon: ID:nGNX5xpn46
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright